Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function (Q42914818)

11 November 2017

Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function (English)

1 reference

11 November 2017

1 reference

5

1 reference

11 November 2017

12

1 reference

11 November 2017

Piotr Ponikowski

1

0 references

Christopher M O'Connor

3

object named as

Christopher M O'Connor

1 reference

11 November 2017

7

Michael M Givertz

1 reference

11 November 2017

6

Barry M Massie

1 reference

11 November 2017

4

Howard Dittrich

1 reference

11 November 2017

10

Beth D Weatherley

1 reference

11 November 2017

Veselin Mitrovic

2

1 reference

11 November 2017

Erluo Chen

8

1 reference

11 November 2017

Meredith Murray

9

1 reference

11 November 2017

Kenji P Fujita

11

1 reference

11 November 2017

7 September 2010

1 reference

European Journal of Heart Failure

11 November 2017

1 reference

11 November 2017

12

1 reference

11 November 2017

11

1 reference

11 November 2017

1238-1246

1 reference

High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database

11 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Worsening renal function and prognosis in heart failure: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Importance of venous congestion for worsening of renal function in advanced decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Relation of loop diuretic dose to mortality in advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Adenosine and kidney function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment e

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Haemodynamic effects of frusemide in patients suspected of having acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Haemodynamic effects of diuretics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Relations between pressure in pulmonary artery, left atrium, and left ventricle with special reference to events at end diastole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Vasodilators in the treatment of acute heart failure: what we know, what we don't

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Adenosine receptor antagonism accounts for the seizure-prolonging effects of aminophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ137

21 January 2018

Identifiers

DOI

10.1093/EURJHF/HFQ137

1 reference

11 November 2017

1 reference